Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06938347 · ClinicalTrials.gov registry record · Phase 3
Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt
A Phase 3 study of Right-To-Left Shunt, sponsored by Agitated Solutions.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 5
- Study locations
NCT06938347: Recruiting Phase 3 study of Right-To-Left Shunt, sponsored by Agitated Solutions.
NCT06938347 is a Phase 3 study of Right-To-Left Shunt that is actively recruiting participants, run by Agitated Solutions. The registered enrollment target is 300 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06938347, a Phase 3 study of Right-To-Left Shunt, is actively recruiting participants, sponsored by Agitated Solutions.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a phase 3, multicenter, open-label, blinded, crossover trial in which each participant will undergo a randomized sequence of ASI-02 and agitated saline standard of care (SoC) via a saline contrast transthoracic echocardiogram (TTE) study.
Conditions Studied
Interventions
- DRUG Agitated Saline SoC
- DRUG ASI-02
Study Locations (5)
Illinois
- Northwestern University - Chicago
Minnesota
- Mayo Clinic - Rochester
Mississippi
- Jackson Heart Clinic - Jackson
New York
- NYU Langone Health - New York
Other
- Toronto General - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-11-05 |
| Est. Completion | 2026-06 |
| Phase | Phase 3 |
What NCT06938347 shows while recruiting
NCT06938347 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Right-To-Left Shunt appearing as the primary indexed condition, and to 2 interventions - of which Agitated Saline SoC is the first listed.
NCT06938347 lists 5 locations in 5 states (Illinois, Minnesota, Mississippi).
Frequently Asked Questions
What is clinical trial NCT06938347 about?
NCT06938347 is a clinical study titled "Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt". This is a phase 3, multicenter, open-label, blinded, crossover trial in which each participant will undergo a randomized sequence of ASI-02 and agitated saline standard of care (SoC) via a saline contrast transthoracic echocardiogram (TTE) study.
What is the current status of trial NCT06938347?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2025-11-05. Estimated completion is 2026-06.
What conditions does trial NCT06938347 study?
This clinical trial studies the following conditions: Right-To-Left Shunt.
What interventions are being tested in trial NCT06938347?
The interventions under investigation include: Agitated Saline SoC (DRUG), ASI-02 (DRUG).
Who is sponsoring clinical trial NCT06938347?
This trial is sponsored by Agitated Solutions, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06938347 being conducted?
This trial has 5 study locations across Illinois, Minnesota, Mississippi, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06938347's enrollment target sits among peer trials
300 1123rd of 2000 higher than 840 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI